nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—ABCB1—colon cancer	0.281	1	CbGaD
Sirolimus—SLCO1B1—Irinotecan—colon cancer	0.0683	0.18	CbGbCtD
Sirolimus—CYP3A7—Irinotecan—colon cancer	0.0401	0.105	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Irinotecan—colon cancer	0.0401	0.105	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—colon cancer	0.0361	0.0951	CbGbCtD
Sirolimus—CYP3A7—Vincristine—colon cancer	0.035	0.0922	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Vincristine—colon cancer	0.035	0.0922	CbGbCtD
Sirolimus—CYP3A5—Irinotecan—colon cancer	0.0301	0.0791	CbGbCtD
Sirolimus—CYP3A5—Vincristine—colon cancer	0.0263	0.0692	CbGbCtD
Sirolimus—ABCB1—Irinotecan—colon cancer	0.0196	0.0515	CbGbCtD
Sirolimus—ABCB1—Vincristine—colon cancer	0.0171	0.045	CbGbCtD
Sirolimus—CYP3A4—Irinotecan—colon cancer	0.0117	0.0309	CbGbCtD
Sirolimus—ABCB1—Methotrexate—colon cancer	0.0104	0.0273	CbGbCtD
Sirolimus—CYP3A4—Vincristine—colon cancer	0.0102	0.027	CbGbCtD
Sirolimus—EIF4E—embryo—colon cancer	0.00498	0.0799	CbGeAlD
Sirolimus—EIF4E—renal system—colon cancer	0.00377	0.0605	CbGeAlD
Sirolimus—MTOR—blood vessel—colon cancer	0.00323	0.0518	CbGeAlD
Sirolimus—EIF4E—lymphoid tissue—colon cancer	0.00313	0.0502	CbGeAlD
Sirolimus—EIF4E—digestive system—colon cancer	0.00309	0.0496	CbGeAlD
Sirolimus—FGF2—smooth muscle tissue—colon cancer	0.00239	0.0383	CbGeAlD
Sirolimus—EIF4E—liver—colon cancer	0.0023	0.037	CbGeAlD
Sirolimus—MTOR—embryo—colon cancer	0.00193	0.0309	CbGeAlD
Sirolimus—FGF2—vagina—colon cancer	0.00166	0.0267	CbGeAlD
Sirolimus—MTOR—epithelium—colon cancer	0.00157	0.0252	CbGeAlD
Sirolimus—MTOR—smooth muscle tissue—colon cancer	0.00151	0.0243	CbGeAlD
Sirolimus—MTOR—renal system—colon cancer	0.00146	0.0234	CbGeAlD
Sirolimus—FKBP1A—epithelium—colon cancer	0.00141	0.0227	CbGeAlD
Sirolimus—FKBP1A—smooth muscle tissue—colon cancer	0.00136	0.0219	CbGeAlD
Sirolimus—FKBP1A—renal system—colon cancer	0.00131	0.0211	CbGeAlD
Sirolimus—MTOR—lymphoid tissue—colon cancer	0.00121	0.0194	CbGeAlD
Sirolimus—MTOR—digestive system—colon cancer	0.0012	0.0192	CbGeAlD
Sirolimus—SLC47A1—renal system—colon cancer	0.00113	0.0181	CbGeAlD
Sirolimus—SLCO1B1—renal system—colon cancer	0.00111	0.0179	CbGeAlD
Sirolimus—MTOR—bone marrow—colon cancer	0.0011	0.0177	CbGeAlD
Sirolimus—FKBP1A—lymphoid tissue—colon cancer	0.00109	0.0175	CbGeAlD
Sirolimus—FGF2—lymph node—colon cancer	0.00108	0.0173	CbGeAlD
Sirolimus—FKBP1A—digestive system—colon cancer	0.00108	0.0173	CbGeAlD
Sirolimus—MTOR—vagina—colon cancer	0.00106	0.017	CbGeAlD
Sirolimus—FKBP1A—bone marrow—colon cancer	0.000992	0.0159	CbGeAlD
Sirolimus—CYP3A7—liver—colon cancer	0.000992	0.0159	CbGeAlD
Sirolimus—FKBP1A—vagina—colon cancer	0.00095	0.0152	CbGeAlD
Sirolimus—SLC47A1—digestive system—colon cancer	0.000925	0.0148	CbGeAlD
Sirolimus—SLCO1B1—digestive system—colon cancer	0.000913	0.0146	CbGeAlD
Sirolimus—MTOR—liver—colon cancer	0.000891	0.0143	CbGeAlD
Sirolimus—CYP3A7-CYP3A51P—liver—colon cancer	0.000843	0.0135	CbGeAlD
Sirolimus—SLC47A1—vagina—colon cancer	0.000816	0.0131	CbGeAlD
Sirolimus—FKBP1A—liver—colon cancer	0.000801	0.0129	CbGeAlD
Sirolimus—Temsirolimus—ABCB1—colon cancer	0.000723	0.532	CrCbGaD
Sirolimus—SLC47A1—liver—colon cancer	0.000689	0.0111	CbGeAlD
Sirolimus—MTOR—lymph node—colon cancer	0.000683	0.011	CbGeAlD
Sirolimus—SLCO1B1—liver—colon cancer	0.00068	0.0109	CbGeAlD
Sirolimus—ABCB1—blood vessel—colon cancer	0.000672	0.0108	CbGeAlD
Sirolimus—Tacrolimus—ABCB1—colon cancer	0.000637	0.468	CrCbGaD
Sirolimus—FKBP1A—lymph node—colon cancer	0.000614	0.00986	CbGeAlD
Sirolimus—CYP3A5—renal system—colon cancer	0.000571	0.00917	CbGeAlD
Sirolimus—SLC47A1—lymph node—colon cancer	0.000528	0.00848	CbGeAlD
Sirolimus—CYP3A5—digestive system—colon cancer	0.000468	0.00752	CbGeAlD
Sirolimus—CYP3A4—renal system—colon cancer	0.000429	0.00688	CbGeAlD
Sirolimus—CYP3A5—vagina—colon cancer	0.000414	0.00664	CbGeAlD
Sirolimus—ABCB1—embryo—colon cancer	0.000401	0.00643	CbGeAlD
Sirolimus—CYP3A4—digestive system—colon cancer	0.000352	0.00564	CbGeAlD
Sirolimus—CYP3A5—liver—colon cancer	0.000349	0.0056	CbGeAlD
Sirolimus—ABCB1—epithelium—colon cancer	0.000327	0.00525	CbGeAlD
Sirolimus—ABCB1—renal system—colon cancer	0.000303	0.00487	CbGeAlD
Sirolimus—CYP3A4—liver—colon cancer	0.000262	0.0042	CbGeAlD
Sirolimus—ABCB1—lymphoid tissue—colon cancer	0.000252	0.00404	CbGeAlD
Sirolimus—ABCB1—digestive system—colon cancer	0.000249	0.00399	CbGeAlD
Sirolimus—ABCB1—bone marrow—colon cancer	0.000229	0.00368	CbGeAlD
Sirolimus—ABCB1—vagina—colon cancer	0.00022	0.00353	CbGeAlD
Sirolimus—Pneumonia—Capecitabine—colon cancer	0.000188	0.00126	CcSEcCtD
Sirolimus—Leukopenia—Fluorouracil—colon cancer	0.000187	0.00125	CcSEcCtD
Sirolimus—Infestation NOS—Capecitabine—colon cancer	0.000186	0.00125	CcSEcCtD
Sirolimus—Infestation—Capecitabine—colon cancer	0.000186	0.00125	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Methotrexate—colon cancer	0.000186	0.00125	CcSEcCtD
Sirolimus—ABCB1—liver—colon cancer	0.000185	0.00298	CbGeAlD
Sirolimus—Discomfort—Irinotecan—colon cancer	0.000183	0.00123	CcSEcCtD
Sirolimus—Neuropathy peripheral—Capecitabine—colon cancer	0.000183	0.00122	CcSEcCtD
Sirolimus—Oedema—Vincristine—colon cancer	0.000182	0.00122	CcSEcCtD
Sirolimus—Anaphylactic shock—Vincristine—colon cancer	0.000182	0.00122	CcSEcCtD
Sirolimus—Stomatitis—Capecitabine—colon cancer	0.000182	0.00122	CcSEcCtD
Sirolimus—Infection—Vincristine—colon cancer	0.000181	0.00121	CcSEcCtD
Sirolimus—Urinary tract infection—Capecitabine—colon cancer	0.000181	0.00121	CcSEcCtD
Sirolimus—Conjunctivitis—Capecitabine—colon cancer	0.000181	0.00121	CcSEcCtD
Sirolimus—Osteoarthritis—Methotrexate—colon cancer	0.00018	0.00121	CcSEcCtD
Sirolimus—Confusional state—Irinotecan—colon cancer	0.000179	0.0012	CcSEcCtD
Sirolimus—Nervous system disorder—Vincristine—colon cancer	0.000179	0.0012	CcSEcCtD
Sirolimus—Thrombocytopenia—Vincristine—colon cancer	0.000179	0.0012	CcSEcCtD
Sirolimus—Haematuria—Capecitabine—colon cancer	0.000178	0.00119	CcSEcCtD
Sirolimus—Anaphylactic shock—Irinotecan—colon cancer	0.000178	0.00119	CcSEcCtD
Sirolimus—Oedema—Irinotecan—colon cancer	0.000178	0.00119	CcSEcCtD
Sirolimus—Chest pain—Fluorouracil—colon cancer	0.000178	0.00119	CcSEcCtD
Sirolimus—Myalgia—Fluorouracil—colon cancer	0.000178	0.00119	CcSEcCtD
Sirolimus—Infection—Irinotecan—colon cancer	0.000177	0.00118	CcSEcCtD
Sirolimus—Hyperhidrosis—Vincristine—colon cancer	0.000176	0.00118	CcSEcCtD
Sirolimus—Hepatobiliary disease—Capecitabine—colon cancer	0.000176	0.00118	CcSEcCtD
Sirolimus—Epistaxis—Capecitabine—colon cancer	0.000176	0.00118	CcSEcCtD
Sirolimus—Discomfort—Fluorouracil—colon cancer	0.000175	0.00118	CcSEcCtD
Sirolimus—Shock—Irinotecan—colon cancer	0.000175	0.00117	CcSEcCtD
Sirolimus—Nervous system disorder—Irinotecan—colon cancer	0.000174	0.00117	CcSEcCtD
Sirolimus—Thrombocytopenia—Irinotecan—colon cancer	0.000174	0.00117	CcSEcCtD
Sirolimus—Anorexia—Vincristine—colon cancer	0.000174	0.00117	CcSEcCtD
Sirolimus—Hyperhidrosis—Irinotecan—colon cancer	0.000172	0.00115	CcSEcCtD
Sirolimus—Confusional state—Fluorouracil—colon cancer	0.000172	0.00115	CcSEcCtD
Sirolimus—Mood swings—Methotrexate—colon cancer	0.000171	0.00114	CcSEcCtD
Sirolimus—Hypotension—Vincristine—colon cancer	0.000171	0.00114	CcSEcCtD
Sirolimus—Anaphylactic shock—Fluorouracil—colon cancer	0.00017	0.00114	CcSEcCtD
Sirolimus—Oedema—Fluorouracil—colon cancer	0.00017	0.00114	CcSEcCtD
Sirolimus—Anorexia—Irinotecan—colon cancer	0.000169	0.00114	CcSEcCtD
Sirolimus—Infection—Fluorouracil—colon cancer	0.000169	0.00113	CcSEcCtD
Sirolimus—Haemoglobin—Capecitabine—colon cancer	0.000168	0.00113	CcSEcCtD
Sirolimus—Rhinitis—Capecitabine—colon cancer	0.000168	0.00112	CcSEcCtD
Sirolimus—Haemorrhage—Capecitabine—colon cancer	0.000167	0.00112	CcSEcCtD
Sirolimus—Nervous system disorder—Fluorouracil—colon cancer	0.000167	0.00112	CcSEcCtD
Sirolimus—Thrombocytopenia—Fluorouracil—colon cancer	0.000167	0.00112	CcSEcCtD
Sirolimus—Hypoaesthesia—Capecitabine—colon cancer	0.000167	0.00112	CcSEcCtD
Sirolimus—Liver function test abnormal—Methotrexate—colon cancer	0.000166	0.00111	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Vincristine—colon cancer	0.000166	0.00111	CcSEcCtD
Sirolimus—Pharyngitis—Capecitabine—colon cancer	0.000166	0.00111	CcSEcCtD
Sirolimus—Tachycardia—Fluorouracil—colon cancer	0.000166	0.00111	CcSEcCtD
Sirolimus—Hypotension—Irinotecan—colon cancer	0.000166	0.00111	CcSEcCtD
Sirolimus—Urinary tract disorder—Capecitabine—colon cancer	0.000165	0.00111	CcSEcCtD
Sirolimus—Insomnia—Vincristine—colon cancer	0.000165	0.00111	CcSEcCtD
Sirolimus—Oedema peripheral—Capecitabine—colon cancer	0.000165	0.00111	CcSEcCtD
Sirolimus—Connective tissue disorder—Capecitabine—colon cancer	0.000165	0.0011	CcSEcCtD
Sirolimus—Urethral disorder—Capecitabine—colon cancer	0.000164	0.0011	CcSEcCtD
Sirolimus—Paraesthesia—Vincristine—colon cancer	0.000164	0.0011	CcSEcCtD
Sirolimus—Breast disorder—Methotrexate—colon cancer	0.000163	0.00109	CcSEcCtD
Sirolimus—Anorexia—Fluorouracil—colon cancer	0.000162	0.00109	CcSEcCtD
Sirolimus—Visual impairment—Capecitabine—colon cancer	0.000161	0.00108	CcSEcCtD
Sirolimus—Insomnia—Irinotecan—colon cancer	0.000161	0.00108	CcSEcCtD
Sirolimus—Paraesthesia—Irinotecan—colon cancer	0.00016	0.00107	CcSEcCtD
Sirolimus—Hypotension—Fluorouracil—colon cancer	0.000159	0.00107	CcSEcCtD
Sirolimus—Decreased appetite—Vincristine—colon cancer	0.000159	0.00106	CcSEcCtD
Sirolimus—Dyspnoea—Irinotecan—colon cancer	0.000158	0.00106	CcSEcCtD
Sirolimus—Somnolence—Irinotecan—colon cancer	0.000158	0.00106	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Vincristine—colon cancer	0.000158	0.00106	CcSEcCtD
Sirolimus—Dyspepsia—Irinotecan—colon cancer	0.000156	0.00105	CcSEcCtD
Sirolimus—Tinnitus—Capecitabine—colon cancer	0.000156	0.00105	CcSEcCtD
Sirolimus—Pain—Vincristine—colon cancer	0.000156	0.00105	CcSEcCtD
Sirolimus—Constipation—Vincristine—colon cancer	0.000156	0.00105	CcSEcCtD
Sirolimus—Asthma—Methotrexate—colon cancer	0.000156	0.00104	CcSEcCtD
Sirolimus—Cardiac disorder—Capecitabine—colon cancer	0.000155	0.00104	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000155	0.00104	CcSEcCtD
Sirolimus—Decreased appetite—Irinotecan—colon cancer	0.000154	0.00104	CcSEcCtD
Sirolimus—Insomnia—Fluorouracil—colon cancer	0.000154	0.00103	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Irinotecan—colon cancer	0.000153	0.00103	CcSEcCtD
Sirolimus—Paraesthesia—Fluorouracil—colon cancer	0.000153	0.00102	CcSEcCtD
Sirolimus—Pancreatitis—Methotrexate—colon cancer	0.000153	0.00102	CcSEcCtD
Sirolimus—Pain—Irinotecan—colon cancer	0.000152	0.00102	CcSEcCtD
Sirolimus—Constipation—Irinotecan—colon cancer	0.000152	0.00102	CcSEcCtD
Sirolimus—Angiopathy—Capecitabine—colon cancer	0.000152	0.00102	CcSEcCtD
Sirolimus—Dyspnoea—Fluorouracil—colon cancer	0.000152	0.00102	CcSEcCtD
Sirolimus—Somnolence—Fluorouracil—colon cancer	0.000151	0.00101	CcSEcCtD
Sirolimus—Immune system disorder—Capecitabine—colon cancer	0.000151	0.00101	CcSEcCtD
Sirolimus—Mediastinal disorder—Capecitabine—colon cancer	0.000151	0.00101	CcSEcCtD
Sirolimus—Chills—Capecitabine—colon cancer	0.00015	0.00101	CcSEcCtD
Sirolimus—Dyspepsia—Fluorouracil—colon cancer	0.00015	0.001	CcSEcCtD
Sirolimus—Gastrointestinal pain—Vincristine—colon cancer	0.000149	0.001	CcSEcCtD
Sirolimus—Decreased appetite—Fluorouracil—colon cancer	0.000148	0.000991	CcSEcCtD
Sirolimus—Pancytopenia—Methotrexate—colon cancer	0.000148	0.000991	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000147	0.000985	CcSEcCtD
Sirolimus—Feeling abnormal—Irinotecan—colon cancer	0.000146	0.000981	CcSEcCtD
Sirolimus—Malnutrition—Capecitabine—colon cancer	0.000146	0.000977	CcSEcCtD
Sirolimus—Dysuria—Methotrexate—colon cancer	0.000146	0.000976	CcSEcCtD
Sirolimus—Neutropenia—Methotrexate—colon cancer	0.000146	0.000976	CcSEcCtD
Sirolimus—Pain—Fluorouracil—colon cancer	0.000146	0.000975	CcSEcCtD
Sirolimus—Gastrointestinal pain—Irinotecan—colon cancer	0.000145	0.000974	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Methotrexate—colon cancer	0.000145	0.00097	CcSEcCtD
Sirolimus—Body temperature increased—Vincristine—colon cancer	0.000144	0.000967	CcSEcCtD
Sirolimus—Abdominal pain—Vincristine—colon cancer	0.000144	0.000967	CcSEcCtD
Sirolimus—Flatulence—Capecitabine—colon cancer	0.000144	0.000962	CcSEcCtD
Sirolimus—Erectile dysfunction—Methotrexate—colon cancer	0.000143	0.000961	CcSEcCtD
Sirolimus—ABCB1—lymph node—colon cancer	0.000142	0.00228	CbGeAlD
Sirolimus—Back pain—Capecitabine—colon cancer	0.000141	0.000945	CcSEcCtD
Sirolimus—Abdominal pain—Irinotecan—colon cancer	0.00014	0.000941	CcSEcCtD
Sirolimus—Body temperature increased—Irinotecan—colon cancer	0.00014	0.000941	CcSEcCtD
Sirolimus—Feeling abnormal—Fluorouracil—colon cancer	0.00014	0.00094	CcSEcCtD
Sirolimus—Muscle spasms—Capecitabine—colon cancer	0.00014	0.000939	CcSEcCtD
Sirolimus—Pneumonia—Methotrexate—colon cancer	0.00014	0.000936	CcSEcCtD
Sirolimus—Infestation NOS—Methotrexate—colon cancer	0.000139	0.00093	CcSEcCtD
Sirolimus—Infestation—Methotrexate—colon cancer	0.000139	0.00093	CcSEcCtD
Sirolimus—Tremor—Capecitabine—colon cancer	0.000137	0.000915	CcSEcCtD
Sirolimus—Stomatitis—Methotrexate—colon cancer	0.000135	0.000907	CcSEcCtD
Sirolimus—Ill-defined disorder—Capecitabine—colon cancer	0.000135	0.000906	CcSEcCtD
Sirolimus—Conjunctivitis—Methotrexate—colon cancer	0.000135	0.000904	CcSEcCtD
Sirolimus—Anaemia—Capecitabine—colon cancer	0.000135	0.000903	CcSEcCtD
Sirolimus—Body temperature increased—Fluorouracil—colon cancer	0.000135	0.000902	CcSEcCtD
Sirolimus—Hypersensitivity—Vincristine—colon cancer	0.000134	0.000901	CcSEcCtD
Sirolimus—Sweating—Methotrexate—colon cancer	0.000133	0.000892	CcSEcCtD
Sirolimus—Haematuria—Methotrexate—colon cancer	0.000132	0.000887	CcSEcCtD
Sirolimus—Malaise—Capecitabine—colon cancer	0.000131	0.000881	CcSEcCtD
Sirolimus—Hepatobiliary disease—Methotrexate—colon cancer	0.000131	0.00088	CcSEcCtD
Sirolimus—Epistaxis—Methotrexate—colon cancer	0.000131	0.000877	CcSEcCtD
Sirolimus—Hypersensitivity—Irinotecan—colon cancer	0.000131	0.000877	CcSEcCtD
Sirolimus—Asthenia—Vincristine—colon cancer	0.000131	0.000877	CcSEcCtD
Sirolimus—Syncope—Capecitabine—colon cancer	0.000131	0.000876	CcSEcCtD
Sirolimus—Leukopenia—Capecitabine—colon cancer	0.00013	0.000874	CcSEcCtD
Sirolimus—Palpitations—Capecitabine—colon cancer	0.000129	0.000863	CcSEcCtD
Sirolimus—Loss of consciousness—Capecitabine—colon cancer	0.000128	0.000858	CcSEcCtD
Sirolimus—Asthenia—Irinotecan—colon cancer	0.000128	0.000854	CcSEcCtD
Sirolimus—Cough—Capecitabine—colon cancer	0.000127	0.000852	CcSEcCtD
Sirolimus—Hypertension—Capecitabine—colon cancer	0.000126	0.000843	CcSEcCtD
Sirolimus—Hypersensitivity—Fluorouracil—colon cancer	0.000125	0.00084	CcSEcCtD
Sirolimus—Haemoglobin—Methotrexate—colon cancer	0.000125	0.000839	CcSEcCtD
Sirolimus—Diarrhoea—Vincristine—colon cancer	0.000125	0.000837	CcSEcCtD
Sirolimus—Haemorrhage—Methotrexate—colon cancer	0.000125	0.000835	CcSEcCtD
Sirolimus—Chest pain—Capecitabine—colon cancer	0.000124	0.000831	CcSEcCtD
Sirolimus—Myalgia—Capecitabine—colon cancer	0.000124	0.000831	CcSEcCtD
Sirolimus—Arthralgia—Capecitabine—colon cancer	0.000124	0.000831	CcSEcCtD
Sirolimus—Pharyngitis—Methotrexate—colon cancer	0.000124	0.000829	CcSEcCtD
Sirolimus—Anxiety—Capecitabine—colon cancer	0.000124	0.000829	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000123	0.000826	CcSEcCtD
Sirolimus—Urinary tract disorder—Methotrexate—colon cancer	0.000123	0.000825	CcSEcCtD
Sirolimus—Discomfort—Capecitabine—colon cancer	0.000123	0.000821	CcSEcCtD
Sirolimus—Urethral disorder—Methotrexate—colon cancer	0.000122	0.000819	CcSEcCtD
Sirolimus—Diarrhoea—Irinotecan—colon cancer	0.000122	0.000815	CcSEcCtD
Sirolimus—Dizziness—Vincristine—colon cancer	0.000121	0.000809	CcSEcCtD
Sirolimus—Pruritus—Fluorouracil—colon cancer	0.00012	0.000807	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—colon cancer	0.00012	0.000805	CcSEcCtD
Sirolimus—Confusional state—Capecitabine—colon cancer	0.00012	0.000804	CcSEcCtD
Sirolimus—Oedema—Capecitabine—colon cancer	0.000119	0.000797	CcSEcCtD
Sirolimus—Infection—Capecitabine—colon cancer	0.000118	0.000792	CcSEcCtD
Sirolimus—Dizziness—Irinotecan—colon cancer	0.000118	0.000787	CcSEcCtD
Sirolimus—Shock—Capecitabine—colon cancer	0.000117	0.000784	CcSEcCtD
Sirolimus—Nervous system disorder—Capecitabine—colon cancer	0.000117	0.000782	CcSEcCtD
Sirolimus—Diarrhoea—Fluorouracil—colon cancer	0.000116	0.00078	CcSEcCtD
Sirolimus—Thrombocytopenia—Capecitabine—colon cancer	0.000116	0.00078	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—colon cancer	0.000116	0.000779	CcSEcCtD
Sirolimus—Tachycardia—Capecitabine—colon cancer	0.000116	0.000778	CcSEcCtD
Sirolimus—Vomiting—Vincristine—colon cancer	0.000116	0.000777	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—colon cancer	0.000116	0.000775	CcSEcCtD
Sirolimus—Skin disorder—Capecitabine—colon cancer	0.000116	0.000774	CcSEcCtD
Sirolimus—Rash—Vincristine—colon cancer	0.000115	0.000771	CcSEcCtD
Sirolimus—Hyperhidrosis—Capecitabine—colon cancer	0.000115	0.00077	CcSEcCtD
Sirolimus—Dermatitis—Vincristine—colon cancer	0.000115	0.00077	CcSEcCtD
Sirolimus—Headache—Vincristine—colon cancer	0.000114	0.000766	CcSEcCtD
Sirolimus—Anorexia—Capecitabine—colon cancer	0.000113	0.00076	CcSEcCtD
Sirolimus—Angiopathy—Methotrexate—colon cancer	0.000113	0.000758	CcSEcCtD
Sirolimus—Vomiting—Irinotecan—colon cancer	0.000113	0.000757	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—colon cancer	0.000113	0.000754	CcSEcCtD
Sirolimus—Dizziness—Fluorouracil—colon cancer	0.000113	0.000754	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—colon cancer	0.000112	0.000753	CcSEcCtD
Sirolimus—Rash—Irinotecan—colon cancer	0.000112	0.000751	CcSEcCtD
Sirolimus—Dermatitis—Irinotecan—colon cancer	0.000112	0.00075	CcSEcCtD
Sirolimus—Chills—Methotrexate—colon cancer	0.000112	0.000749	CcSEcCtD
Sirolimus—Headache—Irinotecan—colon cancer	0.000111	0.000746	CcSEcCtD
Sirolimus—Hypotension—Capecitabine—colon cancer	0.000111	0.000745	CcSEcCtD
Sirolimus—Malnutrition—Methotrexate—colon cancer	0.000108	0.000727	CcSEcCtD
Sirolimus—Nausea—Vincristine—colon cancer	0.000108	0.000726	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000108	0.000726	CcSEcCtD
Sirolimus—Vomiting—Fluorouracil—colon cancer	0.000108	0.000725	CcSEcCtD
Sirolimus—Insomnia—Capecitabine—colon cancer	0.000108	0.000721	CcSEcCtD
Sirolimus—Rash—Fluorouracil—colon cancer	0.000107	0.000719	CcSEcCtD
Sirolimus—Dermatitis—Fluorouracil—colon cancer	0.000107	0.000718	CcSEcCtD
Sirolimus—Paraesthesia—Capecitabine—colon cancer	0.000107	0.000716	CcSEcCtD
Sirolimus—Headache—Fluorouracil—colon cancer	0.000107	0.000715	CcSEcCtD
Sirolimus—Dyspnoea—Capecitabine—colon cancer	0.000106	0.000711	CcSEcCtD
Sirolimus—Nausea—Irinotecan—colon cancer	0.000106	0.000707	CcSEcCtD
Sirolimus—Back pain—Methotrexate—colon cancer	0.000105	0.000703	CcSEcCtD
Sirolimus—Dyspepsia—Capecitabine—colon cancer	0.000105	0.000702	CcSEcCtD
Sirolimus—Decreased appetite—Capecitabine—colon cancer	0.000103	0.000693	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Capecitabine—colon cancer	0.000103	0.000688	CcSEcCtD
Sirolimus—Pain—Capecitabine—colon cancer	0.000102	0.000682	CcSEcCtD
Sirolimus—Constipation—Capecitabine—colon cancer	0.000102	0.000682	CcSEcCtD
Sirolimus—Nausea—Fluorouracil—colon cancer	0.000101	0.000677	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—colon cancer	0.000101	0.000675	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—colon cancer	0.0001	0.000672	CcSEcCtD
Sirolimus—Feeling abnormal—Capecitabine—colon cancer	9.8e-05	0.000657	CcSEcCtD
Sirolimus—Malaise—Methotrexate—colon cancer	9.78e-05	0.000656	CcSEcCtD
Sirolimus—Gastrointestinal pain—Capecitabine—colon cancer	9.73e-05	0.000652	CcSEcCtD
Sirolimus—Leukopenia—Methotrexate—colon cancer	9.71e-05	0.000651	CcSEcCtD
Sirolimus—Cough—Methotrexate—colon cancer	9.47e-05	0.000634	CcSEcCtD
Sirolimus—Body temperature increased—Capecitabine—colon cancer	9.4e-05	0.00063	CcSEcCtD
Sirolimus—Abdominal pain—Capecitabine—colon cancer	9.4e-05	0.00063	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—colon cancer	9.24e-05	0.000619	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—colon cancer	9.24e-05	0.000619	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—colon cancer	9.24e-05	0.000619	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	9.17e-05	0.000615	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—colon cancer	9.13e-05	0.000611	CcSEcCtD
Sirolimus—Confusional state—Methotrexate—colon cancer	8.93e-05	0.000598	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—colon cancer	8.85e-05	0.000593	CcSEcCtD
Sirolimus—Infection—Methotrexate—colon cancer	8.8e-05	0.000589	CcSEcCtD
Sirolimus—Hypersensitivity—Capecitabine—colon cancer	8.76e-05	0.000587	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—colon cancer	8.68e-05	0.000582	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—colon cancer	8.67e-05	0.000581	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—colon cancer	8.6e-05	0.000576	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—colon cancer	8.56e-05	0.000574	CcSEcCtD
Sirolimus—Asthenia—Capecitabine—colon cancer	8.53e-05	0.000572	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—colon cancer	8.44e-05	0.000566	CcSEcCtD
Sirolimus—Pruritus—Capecitabine—colon cancer	8.41e-05	0.000564	CcSEcCtD
Sirolimus—Hypotension—Methotrexate—colon cancer	8.27e-05	0.000554	CcSEcCtD
Sirolimus—Diarrhoea—Capecitabine—colon cancer	8.14e-05	0.000545	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—colon cancer	8.07e-05	0.000541	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—colon cancer	8.01e-05	0.000537	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—colon cancer	7.95e-05	0.000533	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—colon cancer	7.89e-05	0.000529	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—colon cancer	7.87e-05	0.000527	CcSEcCtD
Sirolimus—Dizziness—Capecitabine—colon cancer	7.87e-05	0.000527	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—colon cancer	7.79e-05	0.000522	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—colon cancer	7.7e-05	0.000516	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—colon cancer	7.64e-05	0.000512	CcSEcCtD
Sirolimus—Pain—Methotrexate—colon cancer	7.57e-05	0.000507	CcSEcCtD
Sirolimus—Vomiting—Capecitabine—colon cancer	7.56e-05	0.000507	CcSEcCtD
Sirolimus—Rash—Capecitabine—colon cancer	7.5e-05	0.000503	CcSEcCtD
Sirolimus—Dermatitis—Capecitabine—colon cancer	7.49e-05	0.000502	CcSEcCtD
Sirolimus—Headache—Capecitabine—colon cancer	7.45e-05	0.000499	CcSEcCtD
Sirolimus—Feeling abnormal—Methotrexate—colon cancer	7.3e-05	0.000489	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—colon cancer	7.24e-05	0.000485	CcSEcCtD
Sirolimus—Nausea—Capecitabine—colon cancer	7.06e-05	0.000473	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—colon cancer	7e-05	0.000469	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—colon cancer	7e-05	0.000469	CcSEcCtD
Sirolimus—Hypersensitivity—Methotrexate—colon cancer	6.52e-05	0.000437	CcSEcCtD
Sirolimus—Asthenia—Methotrexate—colon cancer	6.35e-05	0.000426	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—colon cancer	6.26e-05	0.00042	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—colon cancer	6.06e-05	0.000406	CcSEcCtD
Sirolimus—Dizziness—Methotrexate—colon cancer	5.86e-05	0.000392	CcSEcCtD
Sirolimus—Vomiting—Methotrexate—colon cancer	5.63e-05	0.000377	CcSEcCtD
Sirolimus—Rash—Methotrexate—colon cancer	5.58e-05	0.000374	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—colon cancer	5.58e-05	0.000374	CcSEcCtD
Sirolimus—Headache—Methotrexate—colon cancer	5.55e-05	0.000372	CcSEcCtD
Sirolimus—Nausea—Methotrexate—colon cancer	5.26e-05	0.000352	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—BRAF—colon cancer	2.84e-05	0.000226	CbGpPWpGaD
Sirolimus—FGF2—Immune System—FGFR3—colon cancer	2.83e-05	0.000225	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EP300—colon cancer	2.82e-05	0.000224	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—colon cancer	2.8e-05	0.000222	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.78e-05	0.000221	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TGFB1—colon cancer	2.77e-05	0.00022	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—NRAS—colon cancer	2.76e-05	0.000219	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—SRC—colon cancer	2.74e-05	0.000218	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—colon cancer	2.72e-05	0.000216	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—PIK3CA—colon cancer	2.71e-05	0.000215	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—NRAS—colon cancer	2.63e-05	0.000209	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—SRC—colon cancer	2.63e-05	0.000209	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.62e-05	0.000208	CbGpPWpGaD
Sirolimus—FGF2—Disease—FGFR3—colon cancer	2.61e-05	0.000208	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—KRAS—colon cancer	2.57e-05	0.000204	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD8A—colon cancer	2.57e-05	0.000204	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—MYC—colon cancer	2.56e-05	0.000203	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—NRAS—colon cancer	2.53e-05	0.000201	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—colon cancer	2.51e-05	0.0002	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—HRAS—colon cancer	2.51e-05	0.000199	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.43e-05	0.000193	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FGFR3—colon cancer	2.41e-05	0.000192	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTGS2—colon cancer	2.4e-05	0.000191	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—colon cancer	2.4e-05	0.000191	CbGpPWpGaD
Sirolimus—FGF2—Disease—APC—colon cancer	2.4e-05	0.000191	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CDH1—colon cancer	2.39e-05	0.00019	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—KRAS—colon cancer	2.38e-05	0.000189	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.37e-05	0.000188	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.34e-05	0.000186	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—colon cancer	2.3e-05	0.000183	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.29e-05	0.000182	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—KRAS—colon cancer	2.27e-05	0.00018	CbGpPWpGaD
Sirolimus—FGF2—Disease—BRAF—colon cancer	2.25e-05	0.000179	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CTNNB1—colon cancer	2.25e-05	0.000179	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—APC—colon cancer	2.22e-05	0.000176	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—AKT1—colon cancer	2.21e-05	0.000176	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CDKN1A—colon cancer	2.2e-05	0.000175	CbGpPWpGaD
Sirolimus—MTOR—Immune System—BCL2L1—colon cancer	2.2e-05	0.000175	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.19e-05	0.000174	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—PIK3CA—colon cancer	2.18e-05	0.000173	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—colon cancer	2.18e-05	0.000173	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	2.18e-05	0.000173	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—KRAS—colon cancer	2.18e-05	0.000173	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CTNNB1—colon cancer	2.15e-05	0.000171	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CASP3—colon cancer	2.13e-05	0.000169	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	2.12e-05	0.000168	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CDKN1A—colon cancer	2.11e-05	0.000168	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CDKN1A—colon cancer	2.1e-05	0.000167	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FGFR3—colon cancer	2.1e-05	0.000167	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EP300—colon cancer	2.09e-05	0.000166	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—PIK3CA—colon cancer	2.08e-05	0.000166	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—BRAF—colon cancer	2.08e-05	0.000166	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CHST5—colon cancer	2.08e-05	0.000165	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ODC1—colon cancer	2.08e-05	0.000165	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCND1—colon cancer	2.07e-05	0.000165	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	2.06e-05	0.000164	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CTNNB1—colon cancer	2.05e-05	0.000163	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—SRC—colon cancer	2.03e-05	0.000162	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—colon cancer	2.02e-05	0.00016	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CDKN1A—colon cancer	2e-05	0.000159	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—PIK3CA—colon cancer	2e-05	0.000159	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EP300—colon cancer	2e-05	0.000159	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—NRAS—colon cancer	1.96e-05	0.000155	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—SRC—colon cancer	1.95e-05	0.000155	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SRC—colon cancer	1.94e-05	0.000154	CbGpPWpGaD
Sirolimus—MTOR—Disease—FGFR3—colon cancer	1.94e-05	0.000154	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—colon cancer	1.93e-05	0.000153	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—AKT1—colon cancer	1.93e-05	0.000153	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EP300—colon cancer	1.91e-05	0.000152	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.9e-05	0.000151	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.89e-05	0.000151	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NRAS—colon cancer	1.88e-05	0.000149	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NRAS—colon cancer	1.87e-05	0.000149	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.86e-05	0.000148	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SRC—colon cancer	1.86e-05	0.000147	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—colon cancer	1.85e-05	0.000147	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FGFR3—colon cancer	1.83e-05	0.000145	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—colon cancer	1.82e-05	0.000145	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.82e-05	0.000144	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—colon cancer	1.81e-05	0.000144	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NRAS—colon cancer	1.78e-05	0.000142	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—AKT1—colon cancer	1.78e-05	0.000142	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—colon cancer	1.78e-05	0.000142	CbGpPWpGaD
Sirolimus—MTOR—Disease—APC—colon cancer	1.78e-05	0.000141	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ABCB1—colon cancer	1.78e-05	0.000141	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDH1—colon cancer	1.77e-05	0.000141	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—AKT1—colon cancer	1.77e-05	0.000141	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CTNNB1—colon cancer	1.76e-05	0.00014	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.75e-05	0.000139	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TYMS—colon cancer	1.75e-05	0.000139	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—colon cancer	1.74e-05	0.000138	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFB1—colon cancer	1.74e-05	0.000138	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CDKN1A—colon cancer	1.72e-05	0.000137	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—colon cancer	1.71e-05	0.000136	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—colon cancer	1.7e-05	0.000135	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—AKT1—colon cancer	1.7e-05	0.000135	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—colon cancer	1.68e-05	0.000134	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APC—colon cancer	1.68e-05	0.000133	CbGpPWpGaD
Sirolimus—MTOR—Disease—BRAF—colon cancer	1.67e-05	0.000133	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—colon cancer	1.66e-05	0.000132	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFB1—colon cancer	1.66e-05	0.000132	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EP300—colon cancer	1.64e-05	0.00013	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—AKT1—colon cancer	1.63e-05	0.00013	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ABCB1—colon cancer	1.63e-05	0.00013	CbGpPWpGaD
Sirolimus—FGF2—Disease—CTNNB1—colon cancer	1.63e-05	0.000129	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—colon cancer	1.63e-05	0.000129	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—colon cancer	1.62e-05	0.000128	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.61e-05	0.000128	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—colon cancer	1.61e-05	0.000128	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TYMS—colon cancer	1.6e-05	0.000127	CbGpPWpGaD
Sirolimus—FGF2—Immune System—SRC—colon cancer	1.6e-05	0.000127	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDKN1A—colon cancer	1.59e-05	0.000126	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—BRAF—colon cancer	1.58e-05	0.000125	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CASP3—colon cancer	1.56e-05	0.000124	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.56e-05	0.000124	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PIK3CA—colon cancer	1.55e-05	0.000123	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—colon cancer	1.54e-05	0.000122	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRAS—colon cancer	1.53e-05	0.000122	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—colon cancer	1.52e-05	0.000121	CbGpPWpGaD
Sirolimus—FGF2—Disease—EP300—colon cancer	1.51e-05	0.00012	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CTNNB1—colon cancer	1.51e-05	0.00012	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PIK3CA—colon cancer	1.48e-05	0.000118	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PIK3CA—colon cancer	1.48e-05	0.000117	CbGpPWpGaD
Sirolimus—FGF2—Disease—SRC—colon cancer	1.47e-05	0.000117	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1A—colon cancer	1.47e-05	0.000117	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—colon cancer	1.43e-05	0.000114	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—colon cancer	1.42e-05	0.000113	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PIK3CA—colon cancer	1.41e-05	0.000112	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EP300—colon cancer	1.4e-05	0.000111	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—colon cancer	1.4e-05	0.000111	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—colon cancer	1.37e-05	0.000109	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—colon cancer	1.37e-05	0.000109	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—colon cancer	1.37e-05	0.000109	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SRC—colon cancer	1.36e-05	0.000108	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGFR3—colon cancer	1.36e-05	0.000108	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—colon cancer	1.35e-05	0.000107	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.34e-05	0.000107	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—colon cancer	1.33e-05	0.000105	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—colon cancer	1.32e-05	0.000105	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—colon cancer	1.32e-05	0.000105	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.32e-05	0.000105	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—colon cancer	1.32e-05	0.000105	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTNNB1—colon cancer	1.31e-05	0.000104	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—colon cancer	1.31e-05	0.000104	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—colon cancer	1.31e-05	0.000104	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—colon cancer	1.29e-05	0.000103	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1A—colon cancer	1.28e-05	0.000102	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—colon cancer	1.26e-05	0.0001	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APC—colon cancer	1.25e-05	9.91e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARG—colon cancer	1.24e-05	9.83e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—colon cancer	1.22e-05	9.69e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—colon cancer	1.22e-05	9.69e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EP300—colon cancer	1.22e-05	9.67e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—colon cancer	1.22e-05	9.67e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—colon cancer	1.21e-05	9.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—colon cancer	1.21e-05	9.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CTNNB1—colon cancer	1.21e-05	9.61e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—colon cancer	1.21e-05	9.6e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—colon cancer	1.19e-05	9.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—SRC—colon cancer	1.18e-05	9.41e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—colon cancer	1.18e-05	9.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1A—colon cancer	1.18e-05	9.39e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—colon cancer	1.18e-05	9.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BRAF—colon cancer	1.17e-05	9.31e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TYMS—colon cancer	1.16e-05	9.21e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—colon cancer	1.15e-05	9.16e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—colon cancer	1.15e-05	9.16e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CTNNB1—colon cancer	1.14e-05	9.07e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—colon cancer	1.14e-05	9.05e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARG—colon cancer	1.14e-05	9.02e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—colon cancer	1.13e-05	8.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EP300—colon cancer	1.12e-05	8.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—colon cancer	1.12e-05	8.92e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—colon cancer	1.12e-05	8.9e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1A—colon cancer	1.11e-05	8.86e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SRC—colon cancer	1.09e-05	8.69e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EP300—colon cancer	1.06e-05	8.43e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—colon cancer	1.05e-05	8.36e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—colon cancer	1.04e-05	8.25e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—colon cancer	1.04e-05	8.24e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—colon cancer	1.04e-05	8.23e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SRC—colon cancer	1.03e-05	8.2e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—colon cancer	1e-05	7.98e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—colon cancer	1e-05	7.96e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—colon cancer	9.92e-06	7.88e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—colon cancer	9.91e-06	7.88e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—colon cancer	9.8e-06	7.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—colon cancer	9.79e-06	7.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—colon cancer	9.77e-06	7.76e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—colon cancer	9.73e-06	7.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—colon cancer	9.58e-06	7.61e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—colon cancer	9.58e-06	7.61e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—colon cancer	9.24e-06	7.34e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—colon cancer	9.22e-06	7.33e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—colon cancer	9.15e-06	7.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—colon cancer	9.05e-06	7.19e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—colon cancer	9.04e-06	7.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—colon cancer	9e-06	7.16e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—colon cancer	8.93e-06	7.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—colon cancer	8.78e-06	6.98e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TYMS—colon cancer	8.74e-06	6.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—colon cancer	8.55e-06	6.79e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—colon cancer	8.54e-06	6.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CTNNB1—colon cancer	8.47e-06	6.73e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—colon cancer	8.46e-06	6.72e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—colon cancer	8.33e-06	6.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—colon cancer	8.31e-06	6.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1A—colon cancer	8.27e-06	6.57e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARG—colon cancer	8.21e-06	6.52e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—EP300—colon cancer	8.09e-06	6.43e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EP300—colon cancer	7.87e-06	6.25e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—colon cancer	7.84e-06	6.23e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—colon cancer	7.69e-06	6.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SRC—colon cancer	7.65e-06	6.08e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—colon cancer	7.59e-06	6.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—colon cancer	7.45e-06	5.92e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—EP300—colon cancer	7.43e-06	5.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—colon cancer	7.36e-06	5.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—colon cancer	7.36e-06	5.85e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—colon cancer	7.26e-06	5.77e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—colon cancer	6.86e-06	5.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—colon cancer	6.84e-06	5.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—colon cancer	6.79e-06	5.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—colon cancer	6.71e-06	5.33e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—colon cancer	6.46e-06	5.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—colon cancer	6.41e-06	5.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—colon cancer	6.34e-06	5.04e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARG—colon cancer	6.19e-06	4.92e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—colon cancer	5.99e-06	4.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—colon cancer	5.82e-06	4.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—colon cancer	5.63e-06	4.48e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—colon cancer	5.5e-06	4.37e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—colon cancer	5.48e-06	4.36e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMS—colon cancer	5.39e-06	4.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—colon cancer	5.39e-06	4.28e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—EP300—colon cancer	5.37e-06	4.27e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—colon cancer	4.89e-06	3.89e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—colon cancer	4.87e-06	3.87e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—colon cancer	4.76e-06	3.78e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—colon cancer	4.49e-06	3.57e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—EP300—colon cancer	4.05e-06	3.22e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—colon cancer	3.97e-06	3.16e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARG—colon cancer	3.82e-06	3.03e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—colon cancer	3.24e-06	2.58e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—colon cancer	3e-06	2.39e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—colon cancer	3e-06	2.38e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—EP300—colon cancer	2.5e-06	1.98e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—colon cancer	2.45e-06	1.95e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—colon cancer	1.85e-06	1.47e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—colon cancer	1.51e-06	1.2e-05	CbGpPWpGaD
